230 likes | 318 Views
The ‘Lazarus’ Group - increasing joint faith based advocacy on access to medicines. …..for the saving of many lives!.
E N D
The ‘Lazarus’ Group- increasing joint faith based advocacy on access to medicines …..for the saving of many lives!
“Through its impacts on the labour force, households and enterprises, AIDS has played a more significant role in the reversal of human development than any other single factor.” The importance of treatment Personal - lifesaving Generational Relational – stigma reducing Reduces Orphan crisis Economic – local, national Preventative
“A crude scale up to a global level would indicate the global numbers in need of treatment will be in the region of 55 million people by 2030.”
Celebrate saving of life! Vision: Zero new infections, zero discrimination, Zero AIDS-related deaths Revolutionise HIV prevention Catalyse the next phase of treatment, care & support Advance human rights & gender equality for HIV response
HIV Strategy Group • Access to medicines workshop • Own consultation with Pharma Group • Geneva ‘induction’ • Issues to focus on • Updates on MPP, FTA &Treatment 2.0 • Short & long term actions • Group membership • Group name • Mass Campaign idea
Pharma Issues (1) • Innovative new medicine • 20 years patent life • 12 years development (phases 1-3 & 4) • 1 in 100 molecules = ‘success’ • Costs R&D c. $500m • Pharma goals/motives • Shareholder/profit driven • Profits regulated? • Generic versions after 20 years
Basic Treatment Model >80% of 5.2m are generic medicines Excludes using treatment as part of prevention
Pressure is building! Patent Barriers Resistance to first line drugs Need/demand for ARVs Supply/Demand Gap Side Effects Treatment 2.0 including Treatment as Prevention Resources for ARVs
Pharma Issues (2) • WTO • TRIPS = Trade related Intellectual Property Rights • India complied in 2005 • But still more difficult for pharma • LDC – 2016 • Voluntary & Compulsory licenses • TRIPS + • Bilateral Trade Agreements • Data exclusivity
MPP – how it will work? Medicines Patent Pool ‘Rights holders’ Pharma Biotech Research labs Generics companies Royalties
Workshop - Informal feedback • Broad group – good participation in Exercise • Comments – “Pitched at right level” • Focus issues list - growing • Potential group members? • (Could have been longer, non competitive?)
Personal Consultation • Discussions/email with existing members • Some strong commitments • Concern group is german centric • Geneva visit • EAA induction • Credibility of breadth of alliance • MSF • Real technical expertise • MPP • Need help with as much campaign/pressure as possible • Caritas • Strong experience – ‘Prescription for Life/HAART’
Medicines Patent Pool • Needs • Single compounds • Fixed dose combinations • Paediatric formulations • Example • Rilpivirine (Tibotek, J&J) – TMC278 • Low manufacturing cost X10 v efavirenz • Better drug in FDCs • Status • Already in • NIH • In negotiation • Gilead, Sequoia, ViiV, and Roche (preparing), • Not yet • Tibotek, Merck, BMS, Abbot
Treatment 2.0 • Jan 2011 New York • Planning meeting • 5 pillars • Community Mobilisation • 3 Regional Consultations
Bilateral FTAs • E.g. EU-India – Current • Data Exclusivity threat • UK Government Minister – Department for Business Innovation and Skills • Dr Vince Cable • Formal response: “We will continue to argue within Europe that the IP provisions in this FTA should not impact negatively on public health in developing countries, including India itself” • Conclusion April --- June ? • South Africa – EU EPA – potential data exclusivity?
Pharma Group ConsultationPotential focus issues? • Medicines Patent Pool • Bilateral trade agreements • Food (Security) • Children – specific formulations • PMTCT – zero vertical transmission • HIV + TB co-infection • Diagnostics • Side effects – stavudine replacement • Palliative care – increasing cancer (morphine) • Mass mobilisation?
Decision making? Passion/Energy of members Size/Importance of Need Opportunity to have impact
Possible Short term Actions(WG teleconference April) • Action: • Pressure Pharmas not yet in MPP • At all levels • Plus dialogue with Generics companies • Bilateral FTA agreements • Investigate: • Inclusion of food/livelihoods training in donor based programmes • Discuss • Other areas • Mass mobilisation idea?
Additional Members • Criteria • Global(south) • Larger members • Expertise & passion • Expressions of Interest • Stuart Keen (World Vision) • Aginel Chingwaro (UEM) – Papua • Winnie Sseruma (Christian Aid) • Ray Sweety Prem Kumar (India, IT) • Additional Needs (members or advisors) • Doctor, Paediatrician, Pharmacist (MSF?)
Group Name • Pharma Working Group • Access to Medicines? • (Essential?) • Access to Treatment? • Treatment 2.0
Mass mobilisation Campaigns e.g. Caritas and EAA
One idea • Promoted by Joseph story • Hear the voices of beneficiaries • Collective Ecumenical approach • Focus on access issues for children • Build on ‘Prescription for Life’ • Ambitious target; • E.g.1m people by WAD 2012 • Utilise mobile phones to register ‘action’ • Promote through churches – member organisations • Partnership with mobile airtime supplier